Company Filing History:

9 out of 136

Zambon Group S.p.a.

Years Active: 1988-2003

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6589951 - Phthalazine derivatives as phosphodiesterase 4 inhibitors (2003-07-08),

2. 6498160 - Phthalazine derivatives as phosphodiesterase 4 inhibitors (2002-12-24),

3. 6492360 - Phthalazine derivatives phosphodiesterase 4 inhibitors (2002-12-10),

4. 6358973 - Benzazine derivatives as phosphodiesterase 4 inhibitors (2002-03-19),

5. 6340684 - Phthalazine derivatives as phosphodiesterase 4 inhibitors (2002-01-22),

6. 6329370 - Phthalazine derivatives phosphodiesterase 4 inhibitors (2001-12-11),

7. 6297257 - Benzazine derivatives phosphodiesterase 4 inhibitors (2001-10-02),

8. 6232348 - Hydroxymethyl derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene as cardiovascular agent (2001-05-15),

9. 6211387 - Diol compounds as intermediates for preparing antimycotic compounds (2001-04-03),

10. 4766138 - Use of 4-(isoxazolyl)-thiazole-2-oxamic acid derivatives (1988-08-23),

11. 4766137 - 4-(isoxazolyl)-thiazole-2-oxamic acids and derivatives thereof (1988-08-23),

Title: Inventor Giancarlo Grancini: A Pioneer in Phthalazine Derivatives

Introduction

Giancarlo Grancini, an innovative inventor based in Nova Milanese, Italy, has made significant contributions to the field of medicinal chemistry. With an impressive portfolio of 11 patents, his work primarily focuses on developing phosphodiesterase 4 inhibitors, which hold promise in treating various inflammatory diseases.

Latest Patents

Among Grancini's latest patents is a notable invention involving phthalazine derivatives as phosphodiesterase 4 inhibitors. This particular patent outlines compounds of formula (I) wherein B can be alkylene, amino, CONH, or a bond; Cy may be an optionally substituted phenyl or heteroaryl; and R can represent hydrogen, phenyl, or (C)n alkyl, which is optionally substituted. Additional structural elements include (C)n alkyl or polyfluoro(C)n-alkyl, as well as (C)n cycloalkyl that may contain an oxygen atom and is optionally substituted. These compounds, alongside their N→O derivatives and pharmaceutically acceptable salts, act as inhibitors of PDE 4 and TNFα, showcasing their potential therapeutic applications.

Career Highlights

Grancini has enjoyed a fruitful career, during which he has worked with esteemed organizations like Zambon Group S.p.a. and Zambon S.p.a. His expertise in developing innovative pharmaceutical solutions has propelled him into the spotlight within the scientific community.

Collaborations

Throughout his career, Grancini has collaborated with notable colleagues such as Mauro Napoletano and Gabriele Pietro Norcini. These partnerships underline the collaborative spirit of innovation in the field, as they work together to push the boundaries of medicinal research.

Conclusion

In conclusion, Giancarlo Grancini's dedication to developing phthalazine derivatives exemplifies the profound impact individual inventors can have on medicine and pharmaceutical sciences. His patents not only represent significant scientific milestones but also open doors for future advancements in the treatment of inflammatory diseases. As he continues to innovate, the medical community eagerly anticipates the outcomes of his pioneering work.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.